Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 181 of 6351
-
New CAR T-Cell combo trial targets tough hodgkin lymphoma in youth
Disease control Not yet recruitingPatients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Phase 1/2 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Software-Guided heart valve implant aims to boost precision in aortic stenosis
Disease control Not yet recruitingVOYAGER CE Clinical Study using the Encantor TAVI System.
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could Weight-Loss surgery tame a common heart rhythm disorder?
Disease control Not yet recruitingAtrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes …
Phase 4 • Sponsor: Ali Aminian • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug cocktail targets deadliest blood cancers
Disease control Not yet recruitingPatients with high-risk myeloid tumors accompanied by TP53 mutations have a poor survival prognosis, and there are still many unmet treatment needs. The current treatment regimens have many limitations. Selinisol, as a novel export protein inhibitor, has good anti-tumor activity.…
Sponsor: Bing Han • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Targeted drug shows promise for rare vulvar cancer
Disease control Not yet recruitingThis is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate. Patients will receive tisotumab vedotin every 3 we…
Phase 2 • Sponsor: GOG Foundation • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental combo therapy targets Hard-to-Treat HER2+ cancers
Disease control Not yet recruitingThis phase Ib study aims to assess the safety and feasibility of combination of chimeric receptor T cells with trastuzumab in patients with HER2+ solid tumors, with further expansion of study population in HER2+ metastatic breast cancer once safety has been established.
Phase 1/2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for kids with deadly brain cancer: targeted drug trial launches
Disease control Not yet recruitingThe goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question t…
Phase 2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Brain stimulation plus physical therapy: a new hope for FND walking problems?
Disease control Not yet recruitingThe goal of this clinical trial is to test a new treatment for adults with walking problems due to Functional Neurological Disorder (FND). The main question the trial aims to answer is: \- Is stimulation-enhanced physical therapy an effective treatment for walking problems due …
Sponsor: University of Auckland, New Zealand • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a common steroid make hormone therapy work better against breast cancer?
Disease control Not yet recruitingThis is a single centre, open label, phase II clinical study consisting of two parts, each consisting of a different dose of the same intervention to investigate the efficacy of dexamethasone as an adjunct to endocrine therapy in the treatment of ER+ HER2- metastatic breast cance…
Phase 2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Could a joint injection of growth hormone and Platelet-Rich plasma offer a new path for arthritis relief?
Disease control Not yet recruitingThis clinical study will evaluate the efficacy and safety of intra-articular (IA) recombinant human growth hormone (rhGH; somatropin) combined with platelet-rich plasma (PRP) in adults with treatment-resistant knee and ankle osteoarthritis. The study, sponsored by Integrant Pty …
Phase 2/3 • Sponsor: Integrant Pty Ltd • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a targeted pill shrink hard-to-treat bile duct cancers?
Disease control Not yet recruitingThe purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic therapy.
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat GI cancers?
Disease control Not yet recruitingThis study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further evaluation in expansion (RDE). The regimen includes Is…
Phase 1 • Sponsor: Iksuda Therapeutics Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
Disease control Not yet recruitingThe goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily works best to treat adult patients with myelofibrosis in whom the most common approved therapy has failed to adequately control the disease. It will also learn a…
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new eye injection preserve vision in south asians with diabetes?
Disease control Not yet recruitingThe YOSEMITE and RHINE trials, which studied DMO treated with faricimab, had a majority Caucasian cohort, and the small Asian cohort was East Asian, with no South Asian representation. South Asians have a much higher prevalence of diabetes and its ophthalmic complication of DMO. …
Phase 4 • Sponsor: Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can extra doses of an old drug reverse liver scarring?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if treating individuals living in Uganda who have liver fibrosis (scarring) due to schistosomiasis would benefit from more frequent treatment with drug praziquantel. This drug is already approved to treat schistosomiasis and is used glo…
Phase 2/3 • Sponsor: Rhode Island Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can immune checkpoint drugs fight cancers beyond their approved uses?
Disease control Not yet recruitingThis is a phase II therapeutic interventional clinical trial that will evaluate the efficacy, safety, and outcomes of off-label immune checkpoint blockade use across malignancies.
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can two immune boosters outsmart follicular lymphoma without chemo?
Disease control Not yet recruitingThis phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a new antibody rebuild bone in osteoporosis?
Disease control Not yet recruitingThis is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone mass, aged 45-80 years. Approximately 110 participants…
Phase 2 • Sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Olive oil as a shield? trial tests whether a daily spoonful cuts heart risks in HIV
Prevention Not yet recruitingStudy Summary: OLEUM VIHTAEGeneral Information Sponsor: Fundación SEIMC - GESIDA Study Title: Effect of Extra Virgin Olive Oil (EVOO) consumption on the occurrence of cardiovascular events in people living with HIV. Protocol Code: GESIDA 12725 (Version 2.0, Jan 13, 2026) Study D…
Sponsor: Fundacion SEIMC-GESIDA • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Can a tiny implant trap brain tumor cells and make radiation work better?
Disease control Not yet recruitingThis is a prospective, multicenter, single-arm, pilot clinical investigation, aimed at evaluating the safety and preliminary efficacy of the GlioHook implant in patients with high-grade glioma undergoing surgical resection followed by standard of care (SoC) treatment. GlioHook i…
Sponsor: Batea Oncology • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC